In anotherstratified analysis according to type of P2Y12 inhibitor, the results forMACE and death from any cause were consistent with the primary analysis, whilethe risk of myocardial infarction was significantly lower (OR 0.57 [95% CI0.38–0.85], p = 0.005) and the risk of major bleeding was increased inpatients who received ticagrelor monotherapy (OR 1.81 [95% CI 0.99–3.31],p = 0.05). Here, P2RY12 is linked to myocardial infarction.